XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Summary of Significant Accounting Policies (Textual)    
Non-controlling interest rate 21.833%  
Inventory reserve $ 27,500 $ 20,000
Customer discounts, returns and rebates 300,000 $ 1,926,000
Antidilutive securities excluded from computation of earnings per share   16,302,447
Revenue 5,054,706 $ 5,238,604
Accounts receivable reserve 0 37,800
Sales returns and allowances $ 23,200 $ 50,500
Consolidated VIE, description Company consolidated nine VIEs. Company consolidated nine VIEs.
Noncontrolling interests, description The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest's share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.  
Income tax, description More than 50  
Nutraceutical and Cosmetic Additives [Member]    
Summary of Significant Accounting Policies (Textual)    
Concentration risk percentage 25.00% 15.00%
Revenue $ 1,372,879 $ 1,024,264
Finished Cosmetic Products [Member]    
Summary of Significant Accounting Policies (Textual)    
Revenue $ (3,685,277) $ (4,240,640)
Accounts Receivable [Member] | One credit card processor [Member]    
Summary of Significant Accounting Policies (Textual)    
Concentration risk percentage   34.90%
Accounts Receivable [Member] | Two credit card processor [Member]    
Summary of Significant Accounting Policies (Textual)    
Concentration risk percentage   31.60%
Accounts Receivable [Member] | One customer [Member]    
Summary of Significant Accounting Policies (Textual)    
Concentration risk percentage 65.00% 11.00%
Option [Member] | Warrant [Member]    
Summary of Significant Accounting Policies (Textual)    
Antidilutive securities excluded from computation of earnings per share 17,224,919